The design and methodology of premature ejaculation interventional studies

Area of Science:

• Urology
• Sexual Medicine
• Clinical Trial Methodology

Background:

• Large-scale randomized clinical trials (RCTs) are crucial for regulatory approval of new drug treatments.
• Premature ejaculation (PE) lacks standardized clinical trial methodology, hindering reliable efficacy and safety assessments.
• Existing PE definitions and trial designs vary, impacting data interpretability and generalizability.

Purpose of the Study:

• To provide recommendations for ideal premature ejaculation (PE) interventional trial methodology.
• To standardize the definition of study populations, trial design, and efficacy outcome measures for PE trials.
• To enhance the reliability, interpretability, and generalizability of clinical trial data for PE.

Main Methods:

• Review and critique of existing data on clinical trial design, epidemiology, definitions, and psychological impact of PE.
• Application of evidence-based medicine principles for developing standardized recommendations.
• Focus on the International Society for Sexual Medicine (ISSM) multivariate definition of PE for population selection.

Main Results:

• Study populations must be defined by the ISSM multivariate definition of PE for reliable and generalizable trial data.
• Recommended trial design includes double-blind RCT methodology with placebo and/or active drug controls.
• Recommended outcome measures encompass ejaculatory latency time (ELT) and subject/partner-reported outcomes on control, distress, and satisfaction.

Conclusions:

• The ISSM definition of PE represents the state-of-the-art, multi-dimensional understanding and should be the basis for PE clinical trial diagnosis.
• Standardized methodology, including specific population criteria and outcome measures, is essential for robust PE clinical trials.
• Further research is needed to establish clinically significant threshold responses to interventions in PE trials.